丹酚酸C
| 中文名稱 | 丹酚酸C |
|---|---|
| 中文同義詞 | 丹酚酸C(標(biāo)準(zhǔn)品);丹參酚酸C;丹酚酸C;丹酚酸C(丹參酚酸C);丹酚酸C對(duì)照品,;(R,E)-3-(3,4-二羥基苯基)-2-((3-(2-(3,4-二羥基苯基)-7-羥基苯并呋喃-4-基)丙烯?；?氧基)丙酸;標(biāo)準(zhǔn)品對(duì)照品】SALVIANOLIC ACID C;丹參酚酸C標(biāo)準(zhǔn)品,丹參酚酸C對(duì)照品 |
| 英文名稱 | Salvianolicacid C |
| 英文同義詞 | Salvianolicacid C;(alphaR)-alpha-[[(2E)-3-[2-(3,4-Dihydroxyphenyl)-7-hydroxy-4-benzofuranyl]-1-oxo-2-propen-1-yl]oxy]-3,4-dihydroxybenzenepropanoic acid;(2R)-3-(3,4-Dihydroxyphenyl)-2-({(2E)-3-[2-(3,4-dihydroxyphenyl)- 7-hydroxy-1-benzofuran-4-yl]-2-propenoyl}oxy)propanoic acid;Benzenepropanoic acid, α-[[(2E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-4-benzofuranyl]-1-oxo-2-propen-1-yl]oxy]-3,4-dihydroxy-, (αR)-;Benzenepropanoic acid, a-[[(2E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-4-benzofuranyl]-1-oxo-2-propen-1-yl]oxy]-3,4-dihydroxy-,(aR)-;(R,E)-3-(3,4-Dihydroxyphenyl)-2-((3-(2-(3,4-dihydroxyphenyl)-7-hydroxybenzofuran-4-yl)acryloyl)oxy)propanoic acid;(2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-[2-(3,4-dihydroxypheny...;(2R)-3-(3,4-Dihydroxyphenyl)-2-({(2E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-1-benzofuran-4-yl]-2-propenoyl}oxy)propanoicaci |
| CAS號(hào) | 115841-09-3 |
| 分子式 | C26H20O10 |
| 分子量 | 492.43 |
| EINECS號(hào) | |
| 植物來(lái)源 | 丹參 |
| 相關(guān)類別 | 中藥對(duì)照品;標(biāo)準(zhǔn)品;植物提取物;對(duì)照品;植提標(biāo)準(zhǔn)品;分析試劑標(biāo)準(zhǔn)品;標(biāo)準(zhǔn)品-中藥標(biāo)準(zhǔn)品;分析試劑-對(duì)照品;標(biāo)準(zhǔn)品 -中藥標(biāo)準(zhǔn)品;標(biāo)準(zhǔn)品，對(duì)照品;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;標(biāo)準(zhǔn)品-對(duì)照品 |
| Mol文件 | 115841-09-3.mol |
| 結(jié)構(gòu)式 |  |
丹酚酸C 性質(zhì)
| 沸點(diǎn) | 844.2±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.570 |
| 儲(chǔ)存條件 | under inert gas (nitrogen or Argon) at 2-8°C |
| 溶解度 | 溶于甲醇和水 |
| 形態(tài) | 粉末 |
| 酸度系數(shù)(pKa) | 2.76±0.10(Predicted) |
| 顏色 | 粘黃色 |
|
CYP2C8 4.82 μM (Ki) |
CYP2J2 5.75 μM (Ki) |
Salvianolic acid C is a noncompetitive CYP2C8 inhibitor and a moderate mixed inhibitor of CYP2J2, with K i s of 4.82, 5.75 μM for CYP2C8 and CYP2J2, respectively. 1 and 5 μM Salvianolic acid C (SalC) could significantly inhibit the NO production induced by LPS. Salvianolic acid C decreases the expression of iNOS significantly. Salvianolic acid C inhibits LPS-induced TNF-α, IL-1β, IL-6 and IL-10 overproduction. Salvianolic acid C inhibits LPS-induced NF?κB activation. Salvianolic acid C also increases the expression of Nrf2 and HO-1 in BV2 microglial cells.
Salvianolic acid C (20 mg/kg) treatment could significantly decrease the escape latency. In addition, SalC (10 and 20 mg/kg) treatment significantly increase the platform crossing number compared with the LPS model group. Systemic administration of Salvianolic acid C down regulates the brain TNF-α, IL-1β and IL-6 levels compared with the model group. The iNOS and COX-2 levels in rat brain cortex and hippocampus are higher than that in the control group, while Salvianolic acid C treatment significantly down regulates the cortex and hippocampus regions. Salvianolic acid C (5, 10 and 20 mg/kg) treatment dose-dependently increases the p-AMPK, Nrf2, HO-1 and NQO1 levels in rat brain cortex and hippocampus.
藥理藥效:具有一定抗氧化、保護(hù)腦組織細(xì)胞損傷、保護(hù)心腦血管系統(tǒng)和抗HIV作用。
安全信息
| 更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
|---|---|---|---|---|---|
| 2025/02/08 | HY-N0319 | 丹酚酸C Salvianolic acid C | 115841-09-3 | 1 mg | 323元 |
| 2025/02/08 | HY-N0319 | 丹酚酸C Salvianolic acid C | 115841-09-3 | 2 mg | 520元 |